Using an Independent Statistician to Support a Data Monitoring Committee Patrick D. OMeara, Ph.D. Pat OMeara Associates, Inc. [email protected] FDA/Industry.
Emerging Issues with Adaptation of Clinical Trial Design in Drug Development* H.M. James Hung Division of Biometrics I, Office of Biostatistics, OPaSS,
Correcting for Selection Bias in Randomized Clinical Trials Vance W. Berger, NCI 9/15/05 FDA/Industry Workshop, DC.
A Regulatory Perspective on Design and Analysis of Combination Drug Trial* H.M. James Hung Division of Biometrics I, Office of Biostatistics OPaSS, CDER,
FDA/Industry Workshop: Case Studies in M&S Copyright 2006, metrum research group LLC September 29, 2006 1 Exposure-Response (PK-PD) Applied to Model-Based.
1 Bayesian CTS example @ FDA/Industry Workshop September 18, 2003Copyright Pharsight Case Study in the Use of Bayesian Hierarchical Modeling and Simulation.
James Hung, 2004 FDA/Industry Management of Missing Data in Clinical Trials from a Regulatory Perspective H.M. James Hung Div. of Biometrics I, OB/OPaSS/CDER/FDA.
FDA/Industry Workshop September, 19, 2003 Johnson & Johnson Pharmaceutical Research and Development L.L.C. 1 Uses and Abuses of (Adaptive) Randomization:
FDA/Industry Workshop September 14-16, 2005 Critical Path Initiative: What it means for pharmaceutical industry statisticians Walter Offen, Lilly Brenda.
Selection of Differential Expression Genes in Microarray Experiments James J. Chen, Ph.D. Division of Biometry and Risk Assessment National Center for.
Biomarkers and Surrogate Endpoints in Drug Development Technical and Regulatory Considerations Biomarkers and Surrogate Endpoints in Drug Development Technical.
An Introduction to PK/PD Models Part 2 Yaming Hang Biogen Sep. 16, 2015 FDA/Industry Workshop 2015 1.